eMedicine Specialties > General Surgery > Wounds

Wound Care: Treatment

Author: Richard M Stillman, MD, FACS, Honorary Medical Staff, Northwest Medical Center; Former Chief of Staff and Medical Director, Wound Healing Center, Department of Surgery, Northwest Medical Center
Contributor Information and Disclosures

Updated: Sep 29, 2009

Treatment

Medical Therapy

General treatment of nonhealing wounds can be described as follows:

See Treatment of specific types of wounds.

Assess the entire patient

Successful treatment of difficult wounds requires assessment of the entire patient and not just the wound. Systemic problems often impair wound healing; conversely, nonhealing wounds may herald systemic pathology.

Consider the negative effects of endocrine diseases (eg, diabetes, hypothyroidism), hematologic conditions (eg, anemia, polycythemia, myeloproliferative disorders), cardiopulmonary problems (eg, chronic obstructive pulmonary disease, congestive heart failure), GI problems that cause malnutrition and vitamin deficiencies, obesity, and peripheral vascular pathology (eg, atherosclerotic disease, chronic venous insufficiency, lymphedema).

Characterize the wound

Assess the following: (1) size and depth of involvement and the extent of undermining; (2) the appearance of the wound surface, that is, necrotic or viable; (3) amount and characteristics of wound exudate; and (4) status of the periwound tissues (eg, pigmented, scarred, atrophic, cellulitic).

Ensure adequate oxygenation

The usual reason for inadequate tissue oxygenation is local vasoconstriction as a result of sympathetic overactivity. This may occur because of blood volume deficit, unrelieved pain, or hypothermia, especially involving the distal extent of the extremities.

Ensure adequate nutrition

Adequate nutrition is an often-overlooked requirement for normal wound healing.19 Address protein-calorie malnutrition and deficiencies of vitamins and minerals.

Inadequate protein-calorie nutrition, even after just a few days of starvation, can impair normal wound-healing mechanisms. For healthy adults, daily nutritional requirements are approximately 1.25-1.5 g of protein per kilogram of body weight and 30-35 calories/kg. Increase these requirements for those with sizable wounds.

Suspect malnutrition in patients with chronic illnesses, inadequate societal support, multisystemic trauma, or GI or neurologic problems that may impair oral intake. Protein deficiency occurs in approximately 25% of all hospitalized patients.

Chronic malnutrition can be diagnosed by using anthropometric data to compare actual and ideal body weights and by observing low serum albumin levels. Serum prealbumin is sensitive for relatively acute malnutrition because its half-life is 2-3 days (vs 21 d for albumin). A serum prealbumin level of less than 7 g/dL suggests severe protein-calorie malnutrition.

Vitamin and mineral deficiencies also require correction. Vitamin A deficiency reduces fibronectin on the wound surface, reducing cell chemotaxis, adhesion, and tissue repair. Vitamin C is required for the hydroxylation of proline and subsequent collagen synthesis.

Vitamin E, a fat-soluble antioxidant, accumulates in cell membranes, where it protects polyunsaturated fatty acids from oxidation by free radicals, stabilizes lysosomes, and inhibits collagen synthesis. Vitamin E inhibits prostaglandin synthesis by interfering with phospholipase-A2 activity and is therefore anti-inflammatory. Vitamin E supplementation may decrease scar formation.

Zinc is a component of approximately 200 enzymes in the human body, including DNA polymerase, which is required for cell proliferation, and superoxide dismutase, which scavenges superoxide radicals produced by leukocytes during debridement.

Treat infection

Issues to consider are wound infection versus colonization and osteomyelitis.20

A positive wound culture does not confirm a wound infection. Opportunistic microorganisms may colonize any wound. Wound exudate, which is naturally bactericidal, inhibits the spread of surface contamination from becoming a deep wound infection. However, when wound ischemia or systemic immune compromise supervenes, pathogenic microorganisms propagate until an excessive concentration of bacteria in the wound precludes healing. This heralds a true wound infection. Multidrug resistant organisms are becoming increasingly common.

Foul-smelling drainage, a spontaneously bleeding wound bed, flimsy friable tissue, increased levels of wound exudate, increasing pain, surrounding cellulitis, crepitus, necrosis, fasciitis, and regional lymphadenopathy characterize the infected wound. Fever, chills, malaise, leukocytosis, and an elevated erythrocyte sedimentation rate are common systemic manifestations of wound infection.

Wound infection requires surgical debridement and appropriate systemic antibiotic therapy. Topical antiseptics are usually avoided because they interfere with wound healing because of cytotoxicity to healing cells.

Proving the absence of osteomyelitis is often as onerous as establishing its presence. Although osteomyelitis may be associated with fevers, malaise, chronic fatigue, and limited range of motion of the affected extremity, patients often present with only a nonhealing wound or a chronic draining sinus tract overlying a bone or joint.

Plain radiographs, CT scans, radionuclide bone scans, and MRIs have a role in the workup of osteomyelitis. All too often, even a comprehensive imaging evaluation is nondiagnostic. Therefore, negative findings on radiologic workup should not deter the clinician from performing curettage of suspicious bone underlying a chronic draining wound.

Osteomyelitis is treated with surgical curettage and appropriate systemic antibiotics. Provide a wound bed that is conducive to wound healing.

Surgically debride nonvitalized tissue and with appropriate irrigation. Significant amounts of nonviable and fibropurulent tissue must be removed surgically.

Initial aggressive debridement in the operating room with the patient under local anesthesia with sedation or under regional or general anesthesia is often wise. Subsequent debridement in an outpatient setting can be performed by using topical lidocaine gel or spray anesthesia and by gentle excision using iris scissors and forceps or by scraping using a curette.

Dressing changes require clean but not necessarily sterile technique.

Remove foreign bodies

Be attentive to the possibility of foreign bodies, which may prevent healing of traumatic wounds, including road debris and retained fragments of dressing materials or suture material.

Irrigate

Gently irrigate the wound with a physiologic saline solution. If cost is a major consideration, the patient can prepare a saline solution at home by using 1 gallon of distilled water and 8 teaspoons of table salt. The solution is boiled and then cooled to room temperature before use.

If surface exudate is present, consider irrigation under pressure. An irrigation pressure of approximately 8 psi can be achieved with saline forced through a 19-gauge angiocatheter with a 35-mL syringe. Pat the wound surface with soft moist gauze; do not disrupt viable granulation tissue.

Whirlpool treatment is reserved for large and infected wounds.

Provide a moist (not wet) wound bed

After debridement, apply a moist saline dressing, an isotonic sodium chloride gel (eg, Normlgel [Scott Health Care], IntraSite gel), or a hydroactive paste (eg, DuoDerm [ConvaTec]). Optimal wound coverage requires wet-to-damp dressings, which support autolytic debridement, absorb exudate, and protect surrounding normal skin.

A polyvinyl film dressing (eg, OpSite [Smith & Nephew], Tegaderm [3M]), which is semipermeable to oxygen and moisture and impermeable to bacteria, is a good choice for wounds that are neither dry nor highly exudative.

For dry wounds, hydrocolloid dressings, such as DuoDerm or IntraSite hydrocolloid, are impermeable to oxygen, moisture, and bacteria. They maintain a moist environment, and they support autolytic debridement. They are a good choice for relatively desiccated wounds.

For exudative wounds, absorptive dressings, such as calcium alginates (eg, Kaltostat [Calgon Vestal], Curasorb [Kendall]) and hydrofiber dressings (eg, Aquacel and Aquacel-AG [Convatec]), are highly absorptive and are appropriate for exudative wounds. Alginates are available in rope form, which is useful for packing deep wounds.

For very exudative wounds, impregnated gauze dressings, such as Mesalt (Scott), are useful. Twice-daily dressing changes may be needed.

For infected wounds, use silver sulfadiazine (Silvadene) if the patient is not allergic to sulfa drugs. If the patient is allergic to sulfa, bacitracin-zinc ointment is a good alternative. An ionic-silver hydrofiber dressing (Aquacel-AG) is also a good choice.21,22,23,24,25

Bandaging a challenging anatomic area (eg, around a heel ulcer) requires a highly conformable dressing, such as an extra-thin hydrocolloid. Securing a dressing in a highly moist challenging site (eg, around a sacrococcygeal ulcer) requires a conformable and highly adherent dressing, such as a wafer hydrocolloid.

Hydrogel sheets and nonadhesive forms are useful for securing a wound dressing when the surrounding skin is fragile.

Table 1. Characteristics and Uses of Wound-Dressing Materials 

Open table in new window

Table
CategoryExamplesDescriptionApplications
AlginateAlgiSite, Comfeel, Curasorb, Kaltogel, Kaltostat, Sorbsan, TegagelAlginate dressings are made of seaweed extract contains guluronic and mannuronic acids that provide tensile strength and calcium and sodium alginates, which confer an absorptive capacity. Some can leave fibers in the wound if they are not thoroughly irrigated. These dressings are secured with secondary coverage.These dressings are highly absorbent and useful for wounds have copious exudate. Alginate rope is particularly useful to pack exudative wound cavities or sinus tracts.
HydrofiberAquacel, Aquacel-Ag, VersivaAn absorptive textile fiber pad, hydrofiber is also available as a ribbon for packing of deep wounds. This material is covered with a secondary dressing. The hydrofiber combines with wound exudate to produce a hydrophilic gel. Aquacel-Ag contains 1.2% ionic silver that has strong antimicrobial properties against many organisms, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.Hydrofiber absorbent dressings used for exudative wounds.
Debriding agentsHypergel (hypertonic saline gel), Santyl (collagenase), Accuzyme (papain urea)Various products provide some chemical or enzymatic debridement.Debriding agents are useful for necrotic wounds as an adjunct to surgical debridement.
FoamLYOfoam, Spyrosorb, AllevynPolyurethane foam has absorptive capacity.These dressings are useful for cleaning granulating wounds with minimal exudate.
HydrocolloidCombiDERM, Comfeel, DuoDerm CGF Extra Thin, Granuflex, TegasorbHydrocolloid dressings are made of microgranular suspension of natural or synthetic polymers, such as gelatin or pectin, in an adhesive matrix. The granules change from a semihydrated state to a gel as the wound exudate is absorbed.Hydrocolloid dressings are useful for dry necrotic wounds, wounds with minimal exudate and for clean granulating wounds.
HydrogelAquasorb, DuoDerm, Intrasite Gel, Granugel, Normlgel, Nu-Gel, Purilon Gel, KY JellyHydrogel dressings are water-based or glycerin-based semipermeable hydrophilic polymers; cooling properties may decrease wound pain. These gels can lose or absorb water depending upon the state of hydration of the wound. They are secured with secondary covering.These dressings are useful for dry, sloughy, necrotic wounds (eschar).
Low-adherence dressingMepore, Skintact, ReleaseLow-adherence dressings are made of various materials designed to remove easily without damaging underlying skin.These dressings are useful for acute minor wounds, such as skin tears, or as a final dressing for chronic wounds that have nearly healed.
Transparent filmOpSite, Skintact, Release, Tegaderm, BioclusiveTransparent films are highly conformable acrylic adhesive films with no absorptive capacity and little hydrating ability. They may be vapor permeable or perforated.These dressings are useful for clean, dry wounds with minimal exudate. They also are used to secure an underlying absorptive material, to protect high-friction areas and areas that are difficult to bandage (eg, heels) and to secure intravenous catheters.
CategoryExamplesDescriptionApplications
AlginateAlgiSite, Comfeel, Curasorb, Kaltogel, Kaltostat, Sorbsan, TegagelAlginate dressings are made of seaweed extract contains guluronic and mannuronic acids that provide tensile strength and calcium and sodium alginates, which confer an absorptive capacity. Some can leave fibers in the wound if they are not thoroughly irrigated. These dressings are secured with secondary coverage.These dressings are highly absorbent and useful for wounds have copious exudate. Alginate rope is particularly useful to pack exudative wound cavities or sinus tracts.
HydrofiberAquacel, Aquacel-Ag, VersivaAn absorptive textile fiber pad, hydrofiber is also available as a ribbon for packing of deep wounds. This material is covered with a secondary dressing. The hydrofiber combines with wound exudate to produce a hydrophilic gel. Aquacel-Ag contains 1.2% ionic silver that has strong antimicrobial properties against many organisms, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.Hydrofiber absorbent dressings used for exudative wounds.
Debriding agentsHypergel (hypertonic saline gel), Santyl (collagenase), Accuzyme (papain urea)Various products provide some chemical or enzymatic debridement.Debriding agents are useful for necrotic wounds as an adjunct to surgical debridement.
FoamLYOfoam, Spyrosorb, AllevynPolyurethane foam has absorptive capacity.These dressings are useful for cleaning granulating wounds with minimal exudate.
HydrocolloidCombiDERM, Comfeel, DuoDerm CGF Extra Thin, Granuflex, TegasorbHydrocolloid dressings are made of microgranular suspension of natural or synthetic polymers, such as gelatin or pectin, in an adhesive matrix. The granules change from a semihydrated state to a gel as the wound exudate is absorbed.Hydrocolloid dressings are useful for dry necrotic wounds, wounds with minimal exudate and for clean granulating wounds.
HydrogelAquasorb, DuoDerm, Intrasite Gel, Granugel, Normlgel, Nu-Gel, Purilon Gel, KY JellyHydrogel dressings are water-based or glycerin-based semipermeable hydrophilic polymers; cooling properties may decrease wound pain. These gels can lose or absorb water depending upon the state of hydration of the wound. They are secured with secondary covering.These dressings are useful for dry, sloughy, necrotic wounds (eschar).
Low-adherence dressingMepore, Skintact, ReleaseLow-adherence dressings are made of various materials designed to remove easily without damaging underlying skin.These dressings are useful for acute minor wounds, such as skin tears, or as a final dressing for chronic wounds that have nearly healed.
Transparent filmOpSite, Skintact, Release, Tegaderm, BioclusiveTransparent films are highly conformable acrylic adhesive films with no absorptive capacity and little hydrating ability. They may be vapor permeable or perforated.These dressings are useful for clean, dry wounds with minimal exudate. They also are used to secure an underlying absorptive material, to protect high-friction areas and areas that are difficult to bandage (eg, heels) and to secure intravenous catheters.

Consider other topical agents

Topically applied platelet-derived growth factors have a modestly beneficial effect in promoting wound healing. Becaplermin gel 0.01% (Regranex), recombinant human platelet-derived growth factor (PDGF) that is produced through genetic engineering, is approved by the US Food and Drug Administration (FDA) to promote healing of diabetic foot ulcers. Regranex is contraindicated in persons with known skin cancers at the site of application. Freeze-dried, platelet-rich plasma showed promise in an animal study.26

Collagen comprises a significant fraction of the necrotic soft tissues in chronic wounds. The enzyme collagenase, which is derived form fermentation of Clostridium histolyticum, helps remove nonviable tissue from the surface of wounds. However, collagenase is not a substitute for an initial surgical excision of a grossly necrotic wound.

Other topical agents that have been used for wound treatment are sugar, antacids, and vitamin A&D ointment.

Avoid cytotoxic agents, such as hydrogen peroxide, povidone iodine, acetic acid, and Dakin solution (sodium hypochlorite).

Consider compression therapy

Consider the advisability of compression therapy. Compression is appropriate for ulcers caused or exacerbated by extremity edema. Compression may have to be avoided entirely in the presence of significant arterial inflow compromise.

Use support hose or elastic wraps with approximately 40-60 mm Hg of pressure in the absence of arterial disease and 20-30 mm Hg in the presence or suspicion of mild arterial insufficiency.

Manage pain

Manage wound pain by moistening dressings before removal. Consider using 2% topical lidocaine gel during wound care. (Anecdotal reports describe the use of topical morphine and diamorphine-infused gel for palliation of pressure ulcer pain in patients who are terminally ill,27 but this use is not FDA approved.)

Treatment of specific types of wounds can be described as follows:

See General treatment of nonhealing wounds.

Pressure ulcers

Treatment of decubitus ulcers requires prolonged surgical and nursing care.28,29,30,31 During the extended period of treatment required, the patient remains at risk for the development of new pressure ulcers at other sites.32,33,34 Treatment, particularly indications for support surfaces, is based on appropriate staging of the pressure ulcer.35,36

Milne et al reported the outcome of a long-term acute care hospital's program to reduce the incidence of pressure ulcers.37 The facility used a failure mode and effects analysis to determine where improvements in care were most needed. The hospital determined that its ulcer prevalence rates, which were believed to be above average, were associated with such problems as "a lack of 1) wound care professionals, 2) methods to consistently document prevention and wound data, and 3) an interdisciplinary wound care team approach." After the hospital addressed these issues, it saw the incidence of facility-acquired pressure ulcers drop from 41% (the baseline figure) to an average of 4.2%, over a 12-month period.

Table 2. Staging Pressure Ulcers

Open table in new window

Table
StageDefinitionAppearanceAppropriate topical treatmentAverage healing time (d)
INonblanchable erythema of intact skinPink skin that does not resolve when pressure is relieved; discoloration; warmth; indurationDuoDerm q2-3d14
IIPartial-thickness skin loss involving epidermis and/or dermisCracking, blistering, shallow crater, abrasionCleanse with saline; DuoDerm/Tegaderm dressing45
IIIFull-thickness skin loss into subcutaneous fatty tissues or fasciaDistinct ulcer margin; deep crater (in general, 2.075 mm or deeper [the thickness of a nickel])Debride; irrigate with saline; apply DuoDerm/Tegaderm90
IVFull-thickness skin loss with extensive tissue involvement of underlying tissuesExtensive necrosis; damage to underlying supporting structures, such as muscle, bone, tendon, or joint capsuleSurgically debride; irrigate with saline (possibly under pressure); apply advanced topical dressings; consider antibiotics120
StageDefinitionAppearanceAppropriate topical treatmentAverage healing time (d)
INonblanchable erythema of intact skinPink skin that does not resolve when pressure is relieved; discoloration; warmth; indurationDuoDerm q2-3d14
IIPartial-thickness skin loss involving epidermis and/or dermisCracking, blistering, shallow crater, abrasionCleanse with saline; DuoDerm/Tegaderm dressing45
IIIFull-thickness skin loss into subcutaneous fatty tissues or fasciaDistinct ulcer margin; deep crater (in general, 2.075 mm or deeper [the thickness of a nickel])Debride; irrigate with saline; apply DuoDerm/Tegaderm90
IVFull-thickness skin loss with extensive tissue involvement of underlying tissuesExtensive necrosis; damage to underlying supporting structures, such as muscle, bone, tendon, or joint capsuleSurgically debride; irrigate with saline (possibly under pressure); apply advanced topical dressings; consider antibiotics120

*When the overlying skin is necrotic, the staging cannot be accurate until debridement is performed.

  • Debridement: The ulcer often requires surgical excision, usually down to underlying bone. In the absence of erythema, edema, fluctuance, or drainage, clean dry eschar does not need to be debrided surgically but may be softened and allowed to separate using dressings (eg, colloids, hydrogels) that provide a moist environment to encourage autolysis.
  • Topical wound care: Weeks or months of daily dressing changes are required before the wound begins granulating and appears clean enough for myocutaneous flap closure.
  • Treatment of infection: Debridement is a clean, not sterile, procedure. Frequent debridements maintain superficial colonization at acceptable levels. Swab cultures are often meaningless because they reflect only surface colonization of local infection, which does not require antibiotic treatment. In general, systemic antibiotics are not useful unless signs of progressive infection, such as bacteremia, septicemia, progressive cellulitis, or intractable osteomyelitis, are present.
  • Control of chronic wound contamination: Chronic wound contamination because of fecal incontinence can be a vexing problem in typical bedridden patients, who tend to develop sacral and ischial pressure ulcers. (See images below and Images 1-2, 7.) Initial treatment is dietary management. Foods that thicken the stool include applesauce, bananas, boiled milk, bread, cheese, creamy peanut butter, grits, oat bran, oatmeal, pasta, pretzels, rice, tapioca, and yogurt. In rare cases, fecal diversion by means of colostomy is required.
Image of advanced sacral pressure ulcer shows the...

Image of advanced sacral pressure ulcer shows the effects of pressure, shearing, and moisture.

Image of advanced sacral pressure ulcer shows the...

Image of advanced sacral pressure ulcer shows the effects of pressure, shearing, and moisture.


Sacral pressure ulcer before and after flap closu...

Sacral pressure ulcer before and after flap closure.

Sacral pressure ulcer before and after flap closu...

Sacral pressure ulcer before and after flap closure.


Sacral ulcer.

Sacral ulcer.

Sacral ulcer.

Sacral ulcer.

  • Positioning: Patients with pressure ulcers or those at risk for a pressure ulcer should be turned in bed every 2 hours. Patients who are immobile should not be positioned directly on the trochanters; foam wedges and pillows are useful to pad pressure points, to prevent direct contact between bony prominences, and to raise their heels off the bed surface. Pressure ulcers can also be induced by shear forces if patients slide down the bed; therefore, try to use the lowest degree of elevation of the head of the bed that the patient's medical conditions allow.
  • Use of support surfaces
    • Federal regulations (Medicare Bulletin 405) dictate that patients with bedsores or those who are at risk for bedsores must be placed on an appropriate support surface.
    • Federally mandated standards of care dictate what support surfaces are allowable and provide for both civil and criminal penalties for health care entities that fail to comply.
    • Proper prevention and management of pressure ulcers in health care facilities is mandated by federal regulations (Ch IV § 483.25 (c)(1)&(2), 10/1/95), which state, "Based on the comprehensive assessment of a resident, the facility must ensure that (1) a resident who enters the facility without pressure sores does not develop pressure sores unless the individual's clinical condition demonstrates that they were unavoidable, and (2) a resident having pressure sores receives necessary treatment and services to promote healing, prevent infection and prevent new sores from developing."
    • A class I support surface is a simple pressure pad device that is required as follows:
      • For patients who cannot independently change their body position to effectively alleviate pressure
      • For patients who have any stage of pressure ulcer on the trunk or pelvis, plus impaired nutritional status, fecal or urinary incontinence, altered sensory perception, or compromised circulatory status
    • A class II support surface is a pressure-relieving device that reduces pressure over bony prominences to less than 32 mm Hg and that does so for a sustained period. A class II support surface is required as follows:
      • For patients who have multiple pressure ulcers on the trunk or pelvis that has not improved despite a comprehensive treatment, including a class I support surface for a stage II, III, or IV pressure ulcer for at least 1 month
      • For patients who have large or multiple stage III or IV pressure ulcers on the trunk or pelvis
      • For patients who have had a myocutaneous flap or skin graft procedure for a pressure ulcer on the trunk or pelvis within the past 60 days and have been on a class II or III support surface immediately before a recent discharge from a hospital or nursing facility within the past 30 days
    • A class III support surface is an advanced pressure-relieving device. A class III support surface, that is, an air-fluidized bed, may be used only for failure of a comprehensive conservative treatment plan after 30 days. (Note that an air-fluidized bed is contraindicated for any patient with associated severe pulmonary compromise because the absence of firm back support makes coughing ineffective, and the dry air thickens pulmonary secretions.) Such a conservative treatment program includes the following:
      • Education of the patient and the caregiver. A patient information page regarding pressure ulcers is available.30
      • Assessment by a licensed health care practitioner, at least weekly
      • Appropriate turning and positioning
      • Use of a class II support surface
      • Appropriate wound care
      • Appropriate management of incontinence
      • Appropriate nutritional management
Table 3. Support Surfaces

Open table in new window

Table
ClassTypePrincipleExamples
ISimplePressure-relieving pad or mat3- to 5-inch foam mattress, gel overlay, egg-crate mattress
IIAdvancedPowered air* overlay for mattress with low air loss feature; nonpowered advanced pressure-reducing mattress replacement or powered air* floatation bed with or without low air loss featureRoho dry floatation mattress system, Pegasus Renaissance mattress
IIIAir fluidizedFloatation by filtered air* flow pumped through porcelain beadsClinitron bed
ClassTypePrincipleExamples
ISimplePressure-relieving pad or mat3- to 5-inch foam mattress, gel overlay, egg-crate mattress
IIAdvancedPowered air* overlay for mattress with low air loss feature; nonpowered advanced pressure-reducing mattress replacement or powered air* floatation bed with or without low air loss featureRoho dry floatation mattress system, Pegasus Renaissance mattress
IIIAir fluidizedFloatation by filtered air* flow pumped through porcelain beadsClinitron bed


*Long-term use of powered air devices is relatively contraindicated for patients with chronic obstructive lung disease, such as chronic bronchitis, emphysema, and asthma.
  • Proper off-loading for ischial ulcers: Sacral ulcers usually result from prolonged supine bed rest or from shearing forces, particularly because of the patient sliding down the bed when the head is elevated. On the other hand, ischial ulcers often result from prolonged sitting either in the head-up position in the bed or in a wheelchair. Hence, off-loading for ischial ulcer prevention and treatment requires support surfaces for sitting as well as mattress support surfaces. Sitting time must also be limited.
  • Heel protection: Pressure ulcers involving the heel regions commonly occur in patients who are bedridden, even if they are immobilized for just a few days, such as after hip surgery. (See image below and Image 6.) Prevention and treatment of heel pressure ulcers requires off-loading. Off-loading devices are usually selected based on availability and include the following:
    • Booties are simple pressure pads that surround the heel with polyester fibers, iconized fibers, or foam material.
    • Boots are made from a firm outer shell lined with pressure-relief padding. They can also provide positioning capability to help treat contractures and foot drop.
    • Pillows made from polyester and sheepskin fleece or special rubber or plastic interpose a conformable soft overlay between the heel and the mattress.
    • Suspension devices isolate the heel and transfer the weight to the lower leg. These devices also have positioning capabilities that are useful in treating contractures and foot drop.
    • Inflatable devices made from plastic sheets surround the heel and adjacent tissues.
Heel pressure ulcer.

Heel pressure ulcer.

Heel pressure ulcer.

Heel pressure ulcer.


Venous ulcers

Treatment of venous ulcers includes compression therapy, providing a moist wound environment and debridement of necrotic tissue.38,39 Most venous ulcers heal with these measures alone. Some require split-thickness skin grafting or application of bioengineered skin (eg, Apligraf, Dermagraft).40 Pentoxifylline (Trental) and horse chestnut seed (available in supermarkets and health food specialty stores) have been shown to expedite healing of venous stasis ulcers. In some cases, compression therapy is inadequate to maintain healing of venous ulcers, and surgical vein stripping or ligation of venous perforators may be helpful.

A study of 98 limbs with active chronic venous ulcers revealed that all but one had venous reflux; the study also suggested that most of these patients would benefit from surgical or endovascular intervention.41 Other studies suggested a more modest level of benefit from corrective venous surgery.42

Table 4. Compression Bandages for Venous Ulcers*

Open table in new window

Table
TypeDescriptionExamples
Single layerSingle-layer simple tubular woven nylon/elastic bandages may be imprinted with rectangles that stretch to squares when appropriate wrapping tension (30-40 mm Hg) is applied.ACE bandage, Comperm (Conco Medical), Setopress (Seton Healthcare Group)
Three layerThe layers include a padding absorption layer, a compression bandage layer, and a cohesive compression bandage. Bandages may be left in place for up to 1 week depending on wound exudate.Dyna-Flex (Johnson & Johnson)
Four layerThe layers include a nonwoven wound contact layer that is permeable to wound exudate and 4 overlying bandages. Bandages may be left in place for up to 1 week depending on exudate volume.Profore (Smith & Nephew)
Impregnated wrapThe porous flexible occlusive dressing is composed of stretchable gauze and a nonhardening zinc oxide paste.Unna boot (ConvaTec)
TypeDescriptionExamples
Single layerSingle-layer simple tubular woven nylon/elastic bandages may be imprinted with rectangles that stretch to squares when appropriate wrapping tension (30-40 mm Hg) is applied.ACE bandage, Comperm (Conco Medical), Setopress (Seton Healthcare Group)
Three layerThe layers include a padding absorption layer, a compression bandage layer, and a cohesive compression bandage. Bandages may be left in place for up to 1 week depending on wound exudate.Dyna-Flex (Johnson & Johnson)
Four layerThe layers include a nonwoven wound contact layer that is permeable to wound exudate and 4 overlying bandages. Bandages may be left in place for up to 1 week depending on exudate volume.Profore (Smith & Nephew)
Impregnated wrapThe porous flexible occlusive dressing is composed of stretchable gauze and a nonhardening zinc oxide paste.Unna boot (ConvaTec)

*Compression wraps are contraindicated in severe arterial compromise. Some of these products are contraindicated in patients who are allergic to latex.

Diabetic foot ulcers

The treatment of diabetic foot ulcers requires the following: (1) appropriate therapeutic footwear, (2) daily saline or similar dressings to provide a moist wound environment, (3) debridement when necessary, (4) antibiotic therapy if osteomyelitis is present, (5) optimal control of blood glucose, and (6) evaluation and correction of peripheral arterial insufficiency.43,44,45,46,47 See also Diabetic Ulcers.

Wound coverage with cultured human cells or heterogeneic dressings and/or grafts, application of recombinant growth factors, negative pressure wound therapy, and hyperbaric oxygen treatments may also be beneficial.14,48,49,50

Lymphedema

Although lymphedema is not typically a cause of ulceration, ulcers on the extremities may fail to heal because of untreated lymphedema. Nocturnal leg elevation and elastic wraps or support hose are appropriate adjuncts to the treatment of the recalcitrant wound in an edematous extremity. For advanced and nonresponsive lymphedema, complex decongestive physiotherapy is a useful treatment option.

Surgical Therapy

Methods are available to expedite healing of the clean wound. After a wound is in a steady clean state, a decision must be made about allowing it to heal by natural processes or expediting healing with a surgical procedure. Clinical experience and observation of the healing progress in the individual case dictate the appropriate treatment. Surgical options include skin grafting, application of bioengineered skin substitutes, and use of flap closures.

  • Skin grafting: Autologous skin grafting is the criterion standard for viable coverage of partial-thickness wounds. The graft can be harvested with the patient under local anesthesia in an outpatient procedure. Meshing the graft allows wider coverage and promotes drainage of serum and blood.
  • Cadaveric allografting: A cadaveric skin allograft is a useful covering for relatively deep wounds after surgical excision when the wound bed does not appear appropriate for application of an autologous skin graft. The allograft is only a temporary solution.
  • Application of bioengineered skin substitutes46,51,52
    • Apligraf (Organogenesis; Novartis) is a bilayered skin substitute produced by combining bovine collagen and living cells derived from tissue-cultured human infant foreskins. One study of diabetic foot ulcers demonstrated 12-week healing rates of 39% for patients who received only standard wound care versus 56% for those who were treated by application of an Apligraf after a period of standard wound care.
    • Dermagraft (Smith & Nephew, Inc) is human fibroblast-derived dermal substitute manufactured by seeding dermal fibroblasts onto a 3-dimensional bioabsorbable scaffold. It has been marketed for use in the treatment of diabetic foot ulcers, venous ulcers, and pressure sores. A clinical trial showed improved healing rates in diabetic foot ulcers.
    • Oasis (Healthpoint, Ltd), a relatively new product, is a xenogeneic acellular collagen matrix derived from porcine small intestinal submucosa in such a way that an extracellular matrix and natural growth factors remain intact. This provides a scaffold for inducing wound healing.53 Do not use this in patients with allergies to porcine materials.
    • Cultured epithelial autograft (Epicel; Genzyme Tissue Repair, Cambridge, Mass) is an epidermal replacement that is grown in a tissue culture from a skin biopsy taken from the recipient and is cocultured with mouse cells. Preparation of the graft requires about 2 weeks of culture time.
  • Use of flap closures: Delayed primary closure of a chronic wound requires well-vascularized clean tissues and tension-free apposition.54 This usually requires undermining and mobilization of adjacent tissue planes by creating skin flaps or myocutaneous flaps. (See Images 1-2.)

Complications

Complications of nonhealing wounds include the following:

More on Wound Care

Overview: Wound Care
Workup: Wound Care
Treatment: Wound Care
Follow-up: Wound Care
Multimedia: Wound Care
References
Further Reading

References

  1. Frankel H, Sperry J, Kaplan L. Risk factors for pressure ulcer development in a best practice surgical intensive care unit. Am Surg. Dec 2007;73(12):1215-7. [Medline].

  2. Horn SD, Bender SA, Ferguson ML, Smout RJ, Bergstrom N, Taler G, et al. The National Pressure Ulcer Long-Term Care Study: pressure ulcer development in long-term care residents. J Am Geriatr Soc. Mar 2004;52(3):359-67. [Medline].

  3. Bergstrom N, Horn SD, Smout RJ, Bender SA, Ferguson ML, Taler G, et al. The National Pressure Ulcer Long-Term Care Study: outcomes of pressure ulcer treatments in long-term care. J Am Geriatr Soc. Oct 2005;53(10):1721-9. [Medline].

  4. Bergstrom N. Litigation or redesign: improving pressure ulcer prevention. J Am Geriatr Soc. Sep 2005;53(9):1627-9. [Medline].

  5. Abbade LP, Lastória S. Venous ulcer: epidemiology, physiopathology, diagnosis and treatment. Int J Dermatol. Jun 2005;44(6):449-56. [Medline].

  6. Reiber GE, Boyko EJ, Smith DG. Lower extremity foot ulcers and amputations in diabetes. In: Harris MI, ed. Diabetes in America. 2nd ed. Washington, DC: National Institute of Diabetes and Digestive and Kidney Diseases--National Institutes of Health; 1995.

  7. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. Jan 12 2005;293(2):217-28. [Medline].

  8. Chraibi H, Dereure O, Téot L, Guillot B. The diagnosis and treatment of carcinomas occurring at the sites of chronic pressure ulcers. J Wound Care. Nov 2004;13(10):447-8. [Medline].

  9. Mellemkjaer L, Holmich LR, Gridley G, Rabkin C, Olsen JH. Risks for skin and other cancers up to 25 years after burn injuries. Epidemiology. Nov 2006;17(6):668-73. [Medline].

  10. Alam M, Grossman ME, Schneiderman PI, Blume RS, Benvenisty AI. Surgical management of pyoderma gangrenosum: case report and review. Dermatol Surg. Nov 2000;26(11):1063-6. [Medline].

  11. Ehling A, Karrer S, Klebl F, Schäffler A, Müller-Ladner U. Therapeutic management of pyoderma gangrenosum. Arthritis Rheum. Oct 2004;50(10):3076-84. [Medline].

  12. Kang AS, McCarthy JT, Rowland C, Farley DR, van Heerden JA. Is calciphylaxis best treated surgically or medically?. Surgery. Dec 2000;128(6):967-71;discussion 971-2. [Medline].

  13. Ledbetter LS, Khoshnevis MR, Hsu S. Calciphylaxis. Cutis. Jul 2000;66(1):49-51. [Medline].

  14. Arseculeratne G, Evans AT, Morley SM. Calciphylaxis--a topical overview. J Eur Acad Dermatol Venereol. May 2006;20(5):493-502. [Medline].

  15. Bello YM, Phillips TJ. Necrobiosis lipoidica. Indolent plaques may signal diabetes. Postgrad Med. Mar 2001;109(3):93-4. [Medline].

  16. Rachline A, Lariven S, Descamps V, Grossin M, Bouvet E. Leucocytoclastic vasculitis and indinavir. Br J Dermatol. Nov 2000;143(5):1112-3. [Medline].

  17. Chan YC, Valenti D, Mansfield AO, Stansby G. Warfarin induced skin necrosis. Br J Surg. Mar 2000;87(3):266-72. [Medline].

  18. Broughton G 2nd, Janis JE, Attinger CE. Wound healing: an overview. Plast Reconstr Surg. Jun 2006;117(7 Suppl):1e-S-32e-S. [Medline].

  19. Mechanick JI. Practical aspects of nutritional support for wound-healing patients. Am J Surg. Jul 2004;188(1A Suppl):52-6. [Medline].

  20. O'Meara SM, Cullum NA, Majid M, Sheldon TA. Systematic review of antimicrobial agents used for chronic wounds. Br J Surg. Jan 2001;88(1):4-21. [Medline].

  21. Bowler PG, Jones SA, Davies BJ, Coyle E. Infection control properties of some wound dressings. J Wound Care. Nov 1999;8(10):499-502. [Medline].

  22. Driver VR. Silver dressings in clinical practice. Ostomy Wound Manage. Sep 2004;50(9A Suppl):11S-15S. [Medline].

  23. Rayman G, Rayman A, Baker NR, Jurgeviciene N, Dargis V, Sulcaite R, et al. Sustained silver-releasing dressing in the treatment of diabetic foot ulcers. Br J Nurs. Jan 27-Feb 9 2005;14(2):109-14. [Medline].

  24. Leaper DJ. Silver dressings: their role in wound management. Int Wound J. Dec 2006;3(4):282-94. [Medline].

  25. Beam JW. Topical silver for infected wounds. J Athl Train. Sep-Oct 2009;44(5):531-3. [Medline][Full Text].

  26. Pietramaggiori G, Kaipainen A, Czeczuga JM, Wagner CT, Orgill DP. Freeze-dried platelet-rich plasma shows beneficial healing properties in chronic wounds. Wound Repair Regen. Sep-Oct 2006;14(5):573-80. [Medline].

  27. Ashfield T. The use of topical opioids to relieve pressure ulcer pain. Nurs Stand. Jul 20-26 2005;19(45):90-2. [Medline].

  28. Bergstrom N, Bennett MA, Carlson CE. Treatment of pressure ulcers. In: Clinical Practice Guideline, No. 15. Rockville, Md: US Department of Health and Human Services; 1994.

  29. Pompeo M, Baxter C. Sacral and ischial pressure ulcers: evaluation, treatment, and differentiation. Ostomy Wound Manage. Jan 2000;46(1):18-23. [Medline].

  30. Zeller JL, Lynm C, Glass RM. JAMA patient page. Pressure ulcers. JAMA. Aug 23 2006;296(8):1020. [Medline].

  31. Whitney J, Phillips L, Aslam R, Barbul A, Gottrup F, Gould L. Guidelines for the treatment of pressure ulcers. Wound Repair Regen. Nov-Dec 2006;14(6):663-79. [Medline].

  32. [Best Evidence] Reddy M, Gill SS, Rochon PA. Preventing pressure ulcers: a systematic review. JAMA. Aug 23 2006;296(8):974-84. [Medline].

  33. Wilborn D, Halfens R, Dassen T. Pressure ulcer: Prevention protocols and prevalence. J Eval Clin Pract. Dec 2006;12(6):630-8. [Medline].

  34. Halfens RJ. Risk assessment scales for pressure ulcers: a theoretical, methodological, and clinical perspective. Ostomy Wound Manage. Aug 2000;46(8):36-40, 42-4. [Medline].

  35. Dharmarajan TS, Ahmed S. The growing problem of pressure ulcers. Evaluation and management for an aging population. Postgrad Med. May 2003;113(5):77-8, 81-4, 88-90. [Medline].

  36. Sato M, Sanada H, Konya C, Sugama J, Nakagami G. Prognosis of stage I pressure ulcers and related factors. Int Wound J. Dec 2006;3(4):355-62. [Medline].

  37. Milne CT, Trigilia D, Houle TL, et al. Reducing pressure ulcer prevalence rates in the long-term acute care setting. Ostomy Wound Manage. Apr 2009;55(4):50-9. [Medline].

  38. Brem H, Kirsner RS, Falanga V. Protocol for the successful treatment of venous ulcers. Am J Surg. Jul 2004;188(1A Suppl):1-8. [Medline].

  39. Olson JM, Raugi GJ, Nguyen VQ, et al. Guideline concordant venous ulcer care predicts healing in a tertiary care Veterans Affairs Medical Center. Wound Repair Regen. Sep-Oct 2009;17(5):666-70. [Medline].

  40. Cavorsi J, Vicari F, Wirthlin DJ, Ennis W, Kirsner R, O'Connell SM, et al. Best-practice algorithms for the use of a bilayered living cell therapy (Apligraf) in the treatment of lower-extremity ulcers. Wound Repair Regen. Mar-Apr 2006;14(2):102-9. [Medline].

  41. Danielsson G, Arfvidsson B, Eklof B, Kistner RL, Masuda EM, Satoc DT. Reflux from thigh to calf, the major pathology in chronic venous ulcer disease: surgery indicated in the majority of patients. Vasc Endovascular Surg. May-Jun 2004;38(3):209-19. [Medline].

  42. Vowden KR, Vowden P. Preventing venous ulcer recurrence: a review. Int Wound J. Mar 2006;3(1):11-21. [Medline].

  43. Brem H, Sheehan P, Rosenberg HJ, Schneider JS, Boulton AJ. Evidence-based protocol for diabetic foot ulcers. Plast Reconstr Surg. Jun 2006;117(7 Suppl):193S-209S; discussion 210S-211S. [Medline].

  44. Eldor R, Raz I, Ben Yehuda A, Boulton AJ. New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies. Diabet Med. Nov 2004;21(11):1161-73. [Medline].

  45. Frykberg RG, Armstrong DG, Giurini J, Edwards A, Kravette M, Kravitz S, et al. Diabetic foot disorders: a clinical practice guideline. American College of Foot and Ankle Surgeons. J Foot Ankle Surg. 2000;39(5 Suppl):S1-60. [Medline].

  46. McGuigan FX. Skin substitutes as alternatives to autografting in a wartime trauma setting. J Am Acad Orthop Surg. Oct 2006;14(10):S87-9.

  47. Dinh TL, Veves A. Treatment of diabetic ulcers. Dermatol Ther. Nov-Dec 2006;19(6):348-55. [Medline].

  48. Armstrong DG, Lavery LA. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet. Nov 12 2005;366(9498):1704-10. [Medline].

  49. Akbari A, Moodi H, Ghiasi F, Sagheb HM, Rashidi H. Effects of vacuum-compression therapy on healing of diabetic foot ulcers: Randomized controlled trial. J Rehabil Res Dev. 2007;44(5):631-6. [Medline].

  50. Roeckl-Wiedmann I, Bennett M, Kranke P. Systematic review of hyperbaric oxygen in the management of chronic wounds. Br J Surg. Jan 2005;92(1):24-32. [Medline].

  51. Bello YM, Falabella AF, Eaglstein WH. Tissue-engineered skin. Current status in wound healing. Am J Clin Dermatol. 2001;2(5):305-13. [Medline].

  52. Falanga VJ. Tissue engineering in wound repair. Adv Skin Wound Care. May-Jun 2000;13(2 Suppl):15-9. [Medline].

  53. Srivastava A, Jennings LJ, Hanumadass M, Sethi S, DeSagun E, et al. Xenogeneic acellular dermal matrix as a dermal substitute in rats. J Burn Care Rehabil. Sep-Oct 1999;20(5):382-90. [Medline].

  54. Sørensen JL, Jørgensen B, Gottrup F. Surgical treatment of pressure ulcers. Am J Surg. Jul 2004;188(1A Suppl):42-51. [Medline].

Keywords

wound healing, pressure ulcer, diabetic foot, diabetic ulcer, foot ulcer, debridement, decubitus, pressure ulcers, bed sore, bed sores, bedsores, debride, pressure sores, decubitus ulcer, venous ulcer, diabetic feet, decubitus ulcers, debriding, debrided, decubitus ulcers, neuropathic ulcers, venous ulcers, venous stasis ulcers, arterial ulcers, foot ulcers

Contributor Information and Disclosures

Author

Richard M Stillman, MD, FACS, Honorary Medical Staff, Northwest Medical Center; Former Chief of Staff and Medical Director, Wound Healing Center, Department of Surgery, Northwest Medical Center
Richard M Stillman, MD, FACS is a member of the following medical societies: American College of Angiology, American College of Surgeons, Association for Academic Surgery, and Society of University Surgeons
Disclosure: Nothing to disclose.

Medical Editor

Brian James Daley, MD, MBA, FACS, Associate Program Director, Professor, Department of Surgery, Division of Trauma and Critical Care, University of Tennessee School of Medicine
Brian James Daley, MD, MBA, FACS is a member of the following medical societies: American Association for the Surgery of Trauma, American College of Chest Physicians, American College of Surgeons, American Medical Association, Association for Academic Surgery, Association for Surgical Education, Eastern Association for the Surgery of Trauma, Shock Society, Society of Critical Care Medicine, Southeastern Surgical Congress, and Tennessee Medical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Amy L Friedman, MD, Professor of Surgery, Director of Transplantation, State University of New York Upstate Medical University College of Medicine, Syracuse
Amy L Friedman, MD is a member of the following medical societies: American College of Surgeons, American Medical Association, American Medical Women's Association, American Society for Artificial Internal Organs, American Society of Transplant Surgeons, American Society of Transplantation, Association for Academic Surgery, Association of Women Surgeons, International College of Surgeons, International Liver Transplantation Society, New York Academy of Sciences, Pennsylvania Medical Society, Philadelphia County Medical Society, Society of Critical Care Medicine, and Transplantation Society
Disclosure: Nothing to disclose.

Chief Editor

John Geibel, MD, DSc, MA, Vice Chairman, Professor, Department of Surgery, Section of Gastrointestinal Medicine and Department of Cellular and Molecular Physiology, Yale University School of Medicine; Director of Surgical Research, Department of Surgery, Yale-New Haven Hospital
John Geibel, MD, DSc, MA is a member of the following medical societies: American Gastroenterological Association, American Physiological Society, American Society of Nephrology, Association for Academic Surgery, International Society of Nephrology, New York Academy of Sciences, and Society for Surgery of the Alimentary Tract
Disclosure: AMGEN Royalty Other

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.